Posted by Michael Wonder on 27 Jul 2020
Insmed receives positive CHMP opinion for Arikayce liposomal 590 mg nebuliser dispersion for the treatment of NTM lung infections caused by MAC in non-CF patients with limited treatment options
24 July 2020 - If approved, Arikayce will be first and only therapy in the European Union for this difficult to treat condition.
Insmed today announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending Arikayce liposomal 590 mg nebuliser dispersion for the treatment of non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
The European Commission will review the CHMP opinion, with a final decision anticipated in the second half of 2020.
